Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CLNN | PRESS-RELEASE | bearish | 6/10 | Clene reported Q1 2026 EPS of -$0.69 (GAAP), a significant miss versus the -$0.50 consensus, driven by $6.0M in other ex | May 14, 2026 |
| SNYR | PRESS-RELEASE | bearish | 8/10 | Synergy CHC reported a disastrous Q1 2026: revenue collapsed 33% YoY to $5.49M (missing $8.3M consensus by 34%), EPS swu | May 14, 2026 |
| PRE | PRESS-RELEASE | bullish | 6/10 | Prenetics reported preliminary Q1 2026 revenue of $36.0M (vs. $37.9M consensus) and raised full-year 2026 IM8 revenue gu | May 14, 2026 |
| MGTX | PRESS-RELEASE | bullish | 7/10 | MeiraGTx reported Q1 2026 EPS of $0.19, a 142% beat vs consensus of -$0.45, on revenue of $0.3M (well below the $17.0M c | May 14, 2026 |
| BNTC | PRESS-RELEASE | bullish | 6/10 | Benitec Biopharma reported Q3 FY2026 (March 31, 2026) net loss of $0.24/share, beating consensus of -$0.28 by 5.5%. The | May 14, 2026 |
| CMMB | PRESS-RELEASE | neutral | 4/10 | Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduced to $2.4M. The com | May 14, 2026 |
| KROS | PRESS-RELEASE | bearish | 6/10 | Keros Therapeutics reported Q1 2026 EPS of -$1.21, a 31.5% miss vs consensus of -$0.92, and revenue of $0.367M, 78.4% be | May 14, 2026 |
| ASST | PRESS-RELEASE | neutral | 5/10 | Strive announced it will begin paying daily cash dividends on its SATA preferred stock at a 13.00% annualized rate start | May 14, 2026 |
| SUNS | PRESS-RELEASE | bullish | 6/10 | Sunrise Realty Trust reported Q1 2026 Distributable Earnings of $0.35/share, a 29.6% beat vs. $0.27 consensus. The stron | May 14, 2026 |
| AGMB | PRESS-RELEASE | neutral | 2/10 | Agomab Therapeutics announced that management will participate in upcoming industry and investor conferences. This is a | May 14, 2026 |
| FISV | PRESS-RELEASE | neutral | 3/10 | Fiserv announced a strategic collaboration with OpenAI to integrate AI across four areas: agentOS, financial institution | May 14, 2026 |
| EDAP | PRESS-RELEASE | neutral | 3/10 | EDAP TMS announced a non-binding letter of intent with Telix Pharmaceuticals to explore joint clinical research and phys | May 14, 2026 |
| MRLN | PRESS-RELEASE | bearish | 6/10 | Merlin Labs reported Q1 2026 revenue of $1.0M (up from $0.9M YoY) and a GAAP net loss of $(90.4)M, driven by $(87.8)M in | May 14, 2026 |
| LUNR | PRESS-RELEASE | mixed | 6/10 | Intuitive Machines reported Q1 2026 revenue of $186.7M (miss vs $205.3M consensus) and GAAP EPS of -$0.25 (miss vs -$0.0 | May 14, 2026 |
| FTLF | PRESS-RELEASE | mixed | 6/10 | FitLife Brands reported Q1 2026 revenue of $25.3M (+59% YoY), beating the $24.9M consensus, and EPS of $0.17 diluted, be | May 14, 2026 |
| BFRI | PRESS-RELEASE | bullish | 7/10 | Biofrontera reported Q1 2026 revenue of $10.1M (+17% YoY), gross margins expanding to ~80% from ~62%, and near-zero cash | May 14, 2026 |
| GNE | PRESS-RELEASE | bearish | 7/10 | Genie Energy reported Q1 2026 EPS of $0.11, missing the $0.18 consensus by 38.9%, and revenue of $142.3M (above $123.8M | May 14, 2026 |
| CRMD | PRESS-RELEASE | bullish | 7/10 | CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 diluted (30% above $0.33 | May 14, 2026 |
| HCWB | PRESS-RELEASE | bullish | 6/10 | HCW Biologics announced preclinical data showing its fusion immunotherapeutic HCW11-040 prevented bronchopulmonary dyspl | May 14, 2026 |
| INKT | PRESS-RELEASE | bullish | 7/10 | MiNK Therapeutics announced the initiation of a randomized Phase 2 trial (C-1300-02) evaluating its off-the-shelf iNKT c | May 14, 2026 |
| CGTX | PRESS-RELEASE | neutral | 3/10 | Cognition Therapeutics announced a second philanthropic donation to extend its expanded access program (EAP) for zervime | May 14, 2026 |
| MLSS | PRESS-RELEASE | neutral | 4/10 | Milestone Scientific reported Q1 2026 EPS of -$0.01, in line with consensus, and revenue of $2.16M, slightly below the $ | May 14, 2026 |
| ELBM | PRESS-RELEASE | bullish | 7/10 | Electra Battery Materials reported Q1 2026 operating results, highlighting the approval of a US$73M construction budget | May 14, 2026 |
| LUNR | PRESS-RELEASE | bullish | 7/10 | Intuitive Machines announced a definitive agreement to acquire Goonhilly Earth Station Ltd, a UK-based deep space commun | May 14, 2026 |
| CLRB | PRESS-RELEASE | bullish | 6/10 | Cellectar Biosciences reported Q1 2026 EPS of -$1.33, beating the -$1.89 consensus, but remains pre-revenue. The key cat | May 14, 2026 |
| CRWS | PRESS-RELEASE | neutral | 2/10 | Crown Crafts declared a quarterly cash dividend of $0.08 per share on its Series A common stock, payable July 2, 2026 to | May 14, 2026 |
| LIEN | PRESS-RELEASE | neutral | 2/10 | Chicago Atlantic BDC declared a $0.34/share quarterly cash dividend for Q2 2026, payable July 10 to holders of record Ju | May 14, 2026 |
| XRTX | PRESS-RELEASE | bearish | 6/10 | XORTX Therapeutics priced a public offering of ~2.66M shares at $1.88/share for $5M gross proceeds, representing massive | May 14, 2026 |
| AKAM | PRESS-RELEASE | neutral | 5/10 | Akamai Technologies announces the acquisition of LayerX, a browser-based AI usage control provider, for approximately $2 | May 14, 2026 |
| CABA | PRESS-RELEASE | neutral | 4/10 | Cabaletta Bio reported Q1 2026 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39, with no revenue. The miss is marginal | May 14, 2026 |